Influence of race on tolerance of platinum-based chemotherapy and clinical outcomes in women with advanced and recurrent cervical cancer: a pooled analysis of 3 Gynecologic Oncology Group studies.
OBJECTIVE
This study was undertaken to compare toxicity and outcomes from cisplatin-based combination chemotherapy for black and white women with advanced /recurrent cervical cancer.


METHODS
Frequencies of grade 3 and 4 toxicities, response, and survival were compared by race using data from 3 Gynecologic Oncology Group studies.


RESULTS
Black women experienced significantly less grade 3 and 4 neutropenia (63% vs 82%), leukopenia (58% vs 79%), thrombocytopenia (10% vs 23%), and adverse events of any nature (84% vs 93%) compared with white women. Black patients were not at increased risk of disease progression (adjusted relative risk, 1.11; 95% confidence interval, 0.88-1.38; P = .382) or death (adjusted relative risk, 1.02; 95% confidence interval, 0.82-1.26; P = .893).


CONCLUSIONS
Cisplatin-based chemotherapy delivered in a protocol setting for advanced/recurrent carcinoma of the cervix appears better tolerated by black women.
Division of Gynecologic Oncology, University of California, San Diego, San Diego, CA, USA.
Steven C
SC
Plaxe
Sandra E
SE
Brooks
Chunquiao
C
Tian
Jeffrey D
JD
Bloss
David H
DH
Moore
Harry J
HJ
Long
D000970:Antineoplastic Agents / Q000633:toxicity*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000633:toxicity; D044383:Black People; D002945:Cisplatin / Q000633:toxicity*; D018450:Disease Progression; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D012008:Recurrence; D013921:Thrombocytopenia / Q000139:chemically induced; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*; D044465:White People
D000970:Antineoplastic Agents; D002945:Cisplatin